|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010583,
umls-concept:C0014116,
umls-concept:C0025677,
umls-concept:C0030705,
umls-concept:C0069515,
umls-concept:C0205179,
umls-concept:C0229671,
umls-concept:C0242957,
umls-concept:C0441889,
umls-concept:C0442027,
umls-concept:C0445550,
umls-concept:C0678222,
umls-concept:C0871261,
umls-concept:C1306673,
umls-concept:C1335823,
umls-concept:C1521828,
umls-concept:C1704632,
umls-concept:C1705135,
umls-concept:C1706817,
umls-concept:C1825023,
umls-concept:C2911692,
umls-concept:C2931019
|
|
pubmed:issue |
2C
|
|
pubmed:dateCreated |
2004-5-24
|
|
pubmed:abstractText |
The proto-oncogene HER2/neu encodes for a transmembrane receptor protein whose overexpression in breast cancer may be associated with poor prognosis. Its extracellular domain (HER2 ECD) can be shed into the circulation. The purpose of this study was to evaluate the predictive value of HER2 ECD in patients with advanced breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1261-6
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15154657-Administration, Oral,
pubmed-meshheading:15154657-Adult,
pubmed-meshheading:15154657-Aged,
pubmed-meshheading:15154657-Aged, 80 and over,
pubmed-meshheading:15154657-Antineoplastic Agents,
pubmed-meshheading:15154657-Breast Neoplasms,
pubmed-meshheading:15154657-Cyclophosphamide,
pubmed-meshheading:15154657-Dose-Response Relationship, Drug,
pubmed-meshheading:15154657-Female,
pubmed-meshheading:15154657-Humans,
pubmed-meshheading:15154657-Immunohistochemistry,
pubmed-meshheading:15154657-Methotrexate,
pubmed-meshheading:15154657-Middle Aged,
pubmed-meshheading:15154657-Neoplasm Staging,
pubmed-meshheading:15154657-Protein Structure, Tertiary,
pubmed-meshheading:15154657-Receptor, erbB-2,
pubmed-meshheading:15154657-Tumor Markers, Biological
|
|
pubmed:articleTitle |
Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
|
|
pubmed:affiliation |
Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy. maria.sandri@ieo.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
